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Lamb Model of Respiratory Syncytial Virus–Associated Lung Disease:
Insights to Pathogenesis and Novel Treatments
Abstract
Preterm birth is a risk factor for respiratory syncytial virus (RSV) bronchiolitis and hospitalization. The
pathogenesis underlying this is not fully understood, and in vivo studies are needed to better clarify essential
cellular features and molecular mechanisms. Such studies include analysis of lung tissue from affected human
infants and various animal models. The preterm and newborn lamb lung has developmental, structural,
cellular, physiologic, and immunologic features similar to that of human infants. Also, the lamb lung is
susceptible to various strains of RSV that infect infants and cause similar bronchiolar lesions. Studies in lambs
suggest that viral replication in airways (especially bronchioles) is extensive by 4 days after infection, along
with bronchiolitis characterized by degeneration and necrosis of epithelial cells, syncytial cell formation,
neutrophil infiltration, epithelial cell hypertrophy and hyperplasia, and innate and adaptive immune
responses. RSV bronchiolitis greatly affects airflow and gaseous exchange. RSV disease severity is increased in
preterm lambs compared with full-term lambs; similar to human infants. The lamb is conducive to
experimental assessment of novel, mechanistic therapeutic interventions such as delivery of vascular
endothelial growth factor and enhancement of airway epithelial oxidative responses, Club (Clara) cell protein
10, and synthesized compounds such as nanobodies. In contrast, exposure of the fetal ovine lung in vivo to
ethanol, a risk factor for preterm birth, reduces pulmonary alveolar development and surfactant protein A
expression. Because the formalin-inactivated RSV vaccination enhances some inflammatory responses to RSV
infection in lambs, this model has the potential to assess mechanisms of formalin-inactivated RSV enhanced
disease as well as newly developed vaccines.
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Abstract. Preterm birth is a risk factor for respiratory syncytial virus (RSV) bronchiolitis and 
hospitalization.  The pathogenesis underlying this is not fully understood and in vivo studies are 
needed to better clarify essential cellular features and molecular mechanisms.  Such studies 
include analysis of lung tissue from affected human infants and various animal models.  The 
preterm and newborn lamb lung has developmental, structural, cellular, physiologic and 
immunologic features consistent similar to human infants.  Also, the lamb lung is susceptible to 
various strains of RSV that infect infants and cause similar bronchiolar lesions.  Studies in 
lambs suggest that viral replication in airways (especially bronchioles) is extensive by four days 
post-infection along with bronchiolitis characterized by degeneration and necrosis of epithelial 
cells, syncytial cell formation, neutrophil infiltration, epithelial cell hypertrophy and hyperplasia, 
innate and adaptive immune responses. RSV bronchiolitis greatly affects airflow and gaseous 
exchange.  RSV disease severity is increased in preterm lambs compared to full term lambs; 
similar to human infants.  The lamb is conducive to experimental assessment of novel,
mechanistic therapeutic interventions such as delivery of vascular endothelial growth factor 
(VEGF), enhancement of airway epithelial oxidative responses, Clara cell protein 10 (CC10), 
and synthesized compounds such as nanobodies (ALX-0171).  In contrast, exposure of the fetal 
ovine lung in vivo to ethanol, a risk factor for preterm birth, reduces pulmonary alveolar 
development and surfactant protein A expression.  And because the formalin inactivated RSV 
(FI-RSV) vaccination enhances some inflammatory responses to RSV infection in lambs, this 
model has potential to assess mechanisms of FI-RSV enhanced disease as newly developed 
vaccines.
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Introduction. Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory 
infection in infants and young children worldwide,and a leading cause of infantile bronchiolitis
that can result in hospitalization and occasionally death (Aujard and Faurox 2002; Blanken et al. 
2013; Collins and Graham 2008; Collins and Melero 2011; Hon et al. 2012; Welliver et al. 2010). 
Such RSV infections can be worsened by secondary bacterial pathogens (Stark et al. 2006; van 
den Bergh et al. 2012). In industrialized countries, RSV accounts for up to 70% of hospitalized 
bronchiolitis cases (Aujard and Faurox 2002; Collins and Melero 2011; Garcia et al. 2010; Hall 
et al. 2013; Nair et al. 2010; Sommer et al. 2012). However, the mechanistic basis by which 
lung immaturity contributes to increased RSV disease severity is not fully understood. Key 
elements affecting susceptibility of the newborn lung to RSV may include bronchiolar epithelial 
cell immaturity or alterations in the types of cells lining bronchioles such as non-ciliated cells 
(including Clara cells) and type II cells. The ovine lung has much similarity to lung in human 
infants in terms of alveologenesis, airway branching patterns, percentage of Clara cells, and the 
presence of submucosal glands.  This allows studies in lambs demonstrating effects of RSV on 
airway epithelial cell degeneration and necrosis, inflammatory responses, innate (e.g.; 
surfactant proteins, antimicrobial peptides, cytokines, chemokines, dendritic cells, etc.) and 
adaptive (e.g.; Th1, Th2, etc.) immune responses.  Also, the lamb model has been used to 
assess the effects of drugs such as ethanol which can alter bronchiolar epithelial cell 
differentiation/maturation in utero and alter innate and adaptive immune responses.  
Although Palivizumab (Synagis; MedImmune) has potent protective properties and Ribavirin has 
been used in some clinical situations, there are no fully satisfactory vaccines or therapeutic 
regimens (Abed and Bovin 2006; Anderson 2013; Empey et al. 2010; Hon et al. 2012). Thus, 
there is a need to develop new therapeutic approaches that could be used to prevent or treat 
RSV infections and these need to be tested in relevant animal models. Several therapies that
have reduced severity of RSV infection have been tested in lambs and include:  delivery of 
vascular endothelial growth factor (VEGF), enhancement of airway oxidative responses, Clara 
cell protein 10 (CC10) and nanobody (ALX-0171).
RSV disease in humans. RSV is an enveloped, negative strand RNA virus of the family 
Paramyxoviridae, subfamily Pneumovirinae and genus Pneumovirus first discovered in 1952 as 
a lower respiratory tract pathogen of children in their first year of life. RSV most commonly
causes mild respiratory tract disease; however, severe bronchiolitis and pneumonia can occur in 
25-50% of children resulting in ICU admission, supplemental oxygen, mechanical ventilation, 
impaired learning, and death (Aujard and Faurox 2002; Collins and Melero 2011; Espinosa et al. 
2013; Garcia et al. 2010; Hall et al. 2013; Nair et al. 2010; Sommer et al. 2012). World-wide, 
RSV is estimated to cause 199,000 deaths annually in children less than five years of age
(Garcia et al. 2010; Hall et al. 2013; Nair et al. 2010).  Re-infections can occur especially if RSV-
specific neutralizing antibody titers are low.  In the 1960’s a formalin-inactivated RSV (FI-RSV) 
vaccine was associated with enhanced RSV disease severity and two deaths in infants that 
were subsequently infected with RSV (Castilow et al. 2007; Collins and Graham 2008; Collins 
and Melero 2011).  Today, a licensed RSV vaccine is not available. Streptococcus pneumoniae
and Haemophilus influenza are both common respiratory bacterial pathogens that can 
complicate primary RSV and other pulmonary viral infections (Stark et al. 2006; van den Bergh 
et al. 2012).
Therapies, vaccine strategies. Numerous therapeutic compounds against RSV have been 
and are being developed and assessed.  Of, these, ribavirin and Palivizumab have been used in 
hospital settings.  Ribavirin has toxicity issues and Palivizumab is not used universally due to 
set criteria as well as availability and cost issues (Abed and Bovin 2006; Empey et al. 2010; Hon 
et al. 2012; Wu et al. 2008).  Many other innovative and promising therapies are under 
development and testing and include:  antibodies and small molecules against the various RSV 
envelope proteins (F, G, SH), nucleocapsid proteins (N, P, L), nucleocapsid-associated proteins 
(M2-1, M2-2), matrix protein (M1), and nonstructural proteins (NS1, NS2) (Empey et al. 2010).  
These therapies inhibit aspects of RSV replication such as fusion and entry, attachment, virus 
transcription, assembly and cytokine/immune responses.  
The FI-RSV vaccine-related deaths of the 1960’s greatly affected RSV vaccine development.  
Since that event, the mechanistic basis underlying FI-RSV enhanced response has been 
studied extensively (Castillow et al. 2007; Collins and Melero 2011; Delgado et al. 2009).
During this same time, numerous new approaches to RSV vaccination have been developed 
with close attention and care to avoid vaccine-enhanced responses.  Vaccine approaches 
include live virus, vectored (replicating or nonreplicating) and subunit vaccines (Empey et al. 
2010) that utilize attenuated or inactivated RSV, RSV protein(s) adjuvanted or incorporated into 
micro/nanoparticles, epitope scaffolds, virosomes, virus-like particles, virus or bacteria or plant-
based vectors, prime boost vaccination with heterologous vectors (Rudraraju et al. 2013). The 
variety of approaches both enhance the understanding of effective responses to RSV and 
increase the likelihood that a safe and effective vaccine (or vaccines) will be developed.  
Difficulties in developing an RSV vaccine include safety issues that are incumbent for any 
vaccine and the avoidance of vaccine-induced enhanced disease with subsequent RSV 
infection.  Recently, a novel approach has focused on RSV fusion F glycoprotein antigenic site 
Ø, a metastable site specific to the prefusion state which is potent in inducing RSV-neutralizing 
antibodies (McLellan et al. 2013). Immunization with site Ø-stabilized variants of RSV F in mice 
and macaques induced RSV-specific neutralizing activity that protected against RSF infection.
This approach is a break-through for RSV and also a conceptual platform for development of 
vaccines against other viruses.
Animal models of RSV infection. A number of animal models of RSV infection have been 
developed.  As reviewed by Bem, RSV models include Heterologous host-virus models in which 
an animal is infected by human strains of RSV and cognate host-virus models in which an 
animal is infected by a virus closely related to human RSV (Bem et al. 2011).  Heterologous 
host-virus models include:  Chimpanzees, sheep, Cotton rat, and mice; all of which can be 
infected with human strains of RSV.  Cognate host-virus models include cattle which can be 
infected with bovine strains of RSV (bRSV) and mice infected with pneumonia virus of mice 
(PVM), respectively (Bem et al. 2011, Gerschwin 2012; Sacco et al. 2013).  In addition to those 
above, other animals models of human RSV infection include other types of sub-human 
primates (baboons, African green and rhesus monkeys), ferrets, and Chinchillas (Bem et al. 
2011; Eyles et al. 2013).  Of the models above, each has some type of advantage and 
disadvantage depending on the clinical, immunological, cellular or pathogenic aspect of RSV 
disease being investigated.  Other considerations for all animal models include costs,
availability, and ethical considerations.   
Lamb model of RSV infection and insights into RSV pathogenesis. Despite the numerous 
animal models of RSV infection, our laboratory and others have shown that ovine respiratory 
tract, particularly that of lambs, has features well suited for comparison human infants in terms 
of development, structure, susceptibility to human RSV strains, lesion development, immune 
response and clinical features (Derscheid and Ackermann 2012).  In addition, the ovine lung is 
susceptible to respiratory bacterial pathogens that can occur secondary to an initial RSV 
infection as in humans. Alveolar development in humans and lambs occurs prenatally, in 
contrast to the post-natal alveolar development that occurs in rodents (Alcorn et al. 1981; 
Derscheid and Ackermann 2012; Flecknoe et al. 2003; McGowan 2004; Plopper et al. 1983).  
Lamb and infant lung have include similarities in airway branching patterns, relative numbers of 
Clara cells, type II cell development and the presence of airway submucosal glands which
express lactoperoxidase (LPO).  Airway branching in lambs and infants is less truncated than
rodents (Scheerlinck et al. 2008).  Numbers of Clara cells in bronchioles of lambs and infants 
are 18-22% whereas airways of mice are roughly 50% Clara cells (Barth et al. 1994; Derscheid 
and Ackermann 2013; McGowan 2004; Plopper et al. 1983).  We have shown that Clara cells 
and type II cells progressively differentiate with gestational age and have increased surfactant 
protein A (SP-A) and SP-D expression with maturation; both SP-A and SP-D bind and 
aggregate RSV and reduced expression may underlie susceptibility to RSV infection in infants 
born preterm (Derscheid and Ackermann 2013; Meyerholz et al. 2006).  Submucosal glands are 
present in airways of lambs and infants, but absent or at insufficient amounts in rodents to 
produce LPO levels required for an increasing recognized epithelial oxidative system (Derscheid 
and Ackermann 2012; Derscheid and Ackermann 2013; Derscheid et al. 2013; Gerson et al. 
2000; Mestas and Hughes 2004; Pack et al. 1980; Widdicombe et al. 2001; Wijkstrom-Frei et al. 
2003).
RSV pathogenesis and bronchiolitis.  The similarity of lung RSV lesions in sheep and 
ruminants to human RSV pathology has been well-documented by us and others (Derscheid 
and Ackermann 2012; Johnson et al. 2007; Lehmkuhl and Cutlip 1979; Lehmkuhl and Cutlip 
1979).  Lambs are susceptible to bovine and human strains of RSV (Derscheid and Ackermann 
2012; Derscheid et al. 2013; Meehan et al. 1984; Meyerholz et al. 2007; Meyerholz et al. 2004; 
Meyerholz et al. 2004; Olivier et al. 2009; Olivier et al. 2011). We have shown that human RSV 
A2 strain infects lambs and others have shown that the Long strain of RSV infects lambs (Fig. 
1) (Derscheid and Ackermann 2012; Olivier et al. 2009; Olivier et al. 2011).  More recently, we 
have shown that RSV Memphis Strain 37 infects lambs robustly which has compelling 
comparative relevance as the Memphis Strain 37 is used in human clinical trials (Derscheid and 
Ackermann 2012; Derscheid et al. 2013; Derscheid et al. 2013). A pre-term lamb model of RSV 
infection has been developed which has features such as enhanced bronchiolitis, neutrophil 
infiltration, syncytial cell formation, myeloperoxidase production, and enhanced RSV replication 
levels all of which are similar to that seen in preterm human infants (Meyerholz et al. 2004; Sow 
et al. 2010). This model is significant since lambs can be born preterm (90% gestation) and 
survive for such studies whereas rodents do not survive preterm birth.  Whilst 90% gestation is 
not consistent with premature birth in human infants; studies increasing show that even preterm 
birth of infants at 95% gestation (37-38 weeks; e.g., “early term”) have a degree of clinical 
alterations.  Finally, lambs (and other ruminants as well as swine) receive maternal 
immunoglobulin only through the ingestion of colostrum at birth. This biological feature allows
lambs to be deprived of colostrum and thereby lack maternal antibodies to RSV and other 
pathogens thereby eliminating any confounding questions of the effects of maternal antibody on 
clearance of RSV or other pathogens (lambs do not receive maternal antibodies 
transplacentally). This feature is especially useful for vaccination studies and recently it has 
been shown that lambs receiving formalin-inactivated RSV (FI-RSV) vaccine produced
responses which enhanced disease with subsequent RSV infection (Derscheid et al. 2014).  
Clinical parameters in lambs mirror those of human infants in terms of temperature (which is 
variable in both lambs and infants) and enhanced expiratory effort.  Dendritic cell activity as well 
as immune and inflammatory responses in lambs also have consistencies with RSV infection in 
human infants as reviewed previously (Derscheid and Ackermann 2012; Derscheid and 
Ackermann 2013; Fach et al. 2007; Fach et al. 2010; Fach et al. 2007; Sow et al. 2012; Sow et 
al. 2009; Sow et al. 2010; Sow et al. 2011).  
Because of the similarities between lambs and infants outlined above, studies in lambs provide
insight to RSV pathogenesis that cannot be assessed or inferred in studies from human infants,
especially preterm/premature infants due to ethical considerations.  Many RSV studies of 
human RSV infection focus on nasal or bronchoalveolar wash fluids or ciliated cells isolated 
from the upper respiratory tract or continuous cells lines originally generated from the upper 
respiratory tract (Guo-Parke et al. 2013; Pickles 2013; Villenave et al. 2013). These fluids and 
cells are more readily available than bronchiolar fluids and cells.  In lambs and from reports of 
human infants with severe RSV disease, lesions are especially intense in the distal bronchi, 
bronchioles and terminal airways/alveoli. Clinically, this is significant as infants often do not 
become hospitalized or die from RSV rhinitis, tracheitis or upper bronchitis; severe RSV is 
moreso associated with RSV – induced bronchiolitis.  This is due, at least in part, to:  1) the 
tropism of RSV to the bronchiolar epithelium and 2) the narrow lumen of the bronciholes and 
distal airway, 3) low airflow pressure at this level and 4) alterations in airway dilation due to 
inflammation (Tayyari et al. 2011).  In lambs and human infants with severe RSV, RSV infected 
bronchiolar epithelial cells undergo apoptosis/necrosis and subsequent cell debris from the 
degenerate/necrotic epithelial cells along with infiltrating neutrophils and macrophages, mucin, 
and seroproteinaceous fluid partially occlude the lumen of these airways.  In addition, 
bronchiolar epithelial cells adjacent to the RSV-infected epithelial cells undergo hyperplasia in 
order to repair the areas damaged by RSV-induced degeneration and necrosis and this 
hyperplasia further narrows airway lumens. In addition to having a narrow and partially 
occluded lumen, the bronchiole has a relatively weak level of airflow compared to the upper 
respiratory tract and thus it is difficult to expel intraluminal exudates by coughing and enhanced 
expiration. Also, peribronchiolar infiltrates of lymphocytes and plasma cells present in the 
airway adventitia have physical effect on alter airway dilation. Moreover, the cytokines, 
chemokines and other inflammatory mediators present further affect lung physiology at this 
location. Thus, the bronchiole is, in a way, an unfortunate location for RSV to replicate as it is 
an essential conduit for airflow through a narrow lumen with poor airflow pressures.  Thus
gaseous exchange in the alveoli immediately adjacent is profoundly affected. In preterm infants 
and preterm/newborn lambs, many of the above are exacerbated by increased level of RSV 
replication that occurs in both infants and lambs. The increased RSV replication that occurs 
triggers enhanced bronchiolar lesions and exudate accumulation which obstructs airflow.  
Why does RSV replicate at higher levels preterm and in newborns?  This poorly understood but 
considerations include the cell types present in bronchiole (Clara cells and other non-ciliated 
cells), the extent of maturation of these cells at preterm and in newborns, RSV receptor 
expression, and extent/intensity of innate and adaptive immunity responses in this location. The 
bronchiole is a difficult microenvironment to study as the cells are difficult to isolated and grow in 
culture and the airflow, blood flow, and other physiologic conditions are difficult to replicate in 
vitro.  Thus, in vivo models are essential for shedding new light on the mechanistic basis of RSV 
bronchiolitis and lesion development. For example, using laser capture microdissection 
bronchiolar epithelial cells from preterm and term lambs had significant differences in SP-A and 
other innate immune responses in both preterm and term lambs with and without RSV infection 
(Gallup et al. 2005; Kawashima et al. 2006; Meyerholz et al. 2006; Sow et al. 2009).  And in
recent studies in RSV-infected lambs, we have determined that syncytial cell formation occurs 
by three days post RSV inoculation and epithelial hyperplasia is present at four days post 
inoculation; viral titers appear to peak at day four but bronchiolar lesions develop a bit furtherer 
and peak at five and six days post RSV infection when RSV titers are beginning to decrease.  
By days 8 and 14, RSV titers are minimal and lesions are resolving. A more in-depth 
understanding of the kinetics of RSV bronchiolitis is needed in animal models to identify 
features not readily accessible in human infants.
Assessment of therapies in lambs.
Vascular endothelial growth factor (VEGF). VEGF is essential for fetal lung development 
and maturation and also has numerous other activities including: endothelial cell proliferation, 
enhancement of SP-A by lung epithelial cells, and monocyte chemotaxis (Brown et al. 2001; 
Meyerholz et al. 2006; Voelkel et al. 2006).  Because of these activities, we developed the 
hypothesis that VEGF may reduce RSV disease severity in newborn lung.  We discovered that 
pre-treatment of lambs with vascular endothelial growth factor (VEGF) protects lambs from RSV 
infection (Meyerholz et al. 2007; Olivier et al. 2011) (Fig. 2). VEGF reduced disease severity 
against both a bovine strain of RSV and a human strain (hRSV A2) of RSV.  The mechanistic 
basis by which VEGF protects is not known but could be related to VEGF effects on epithelial 
cell differentiation, maturation, and/or expression of SP-A.  Alternatively or in addition, VEGF 
protection may be mediated by recruitment of alveolar macrophages.  Low doses of VEGF do 
not alter the number of alveolar macrophages within the ovine lung; however, higher doses 
induce infiltration of a relatively uniform population of alveolar macrophages into alveoli and 
distal airways (Meyerholz et al. 2006). VEGF can affect many additional inflammatory and 
immune responses that could mediate protection against RSV infection.
Dual functioning oxidase (Duox)/lactoperoxidase (LPO) defense. Accumulating data 
suggest that an oxidative host defense system contributes to airway sterility (Bae et al. 2010; 
Banfi 2007; Fischer 2009; Lorentzen et al. 2011; Moskwa et al. 2007). We and others have 
shown that the oxidative system kills bacteria by producing OSCN- in a lactoperoxidase (LPO)-
catalyzed reaction: H2O2+SCN- Æ OSCN- (Banfi 2007; Derscheid et al. 2013; Fischer et al. 
2011; Fischer 2009). OSCN- production requires three processes working in concert: 1) LPO 
secreted by submucosal glands, 2) H2O2 generated by dual oxidases (Duox) of airway epithelia, 
and 3) SCN- secretion (Banfi 2007; Belding et al. 1970; Conner et al. 2007; Conner et al. 2002; 
Dohan et al. 2003; Fischer et al. 2007; Forteza et al. 2005; Fragoso et al. 2004; Furtmueller et 
al. 2002; Harper et al. 2005). The mechanism(s) by which OSCN- eliminates microbes is not 
known, but OSCN- can oxidize thiol groups in surface proteins (Fischer et al. 2011; Klebanoff 
1967). Importantly, OSCN- is not toxic to eukaryotic cells. LPO has high affinity for SCN- and 
also I- (Fragoso et al. 2004; Furtmueller et al. 2002). LPO can catalyze the oxidation of I- to OI-
in the presence of H2O2 (Furtmueller et al. 2002; Gattas et al. 2009). Although I- is not a 
physiological component of the airway surface liquid (ASL), when present, I- allows HOI 
generation by the LPO/Duox enzymes. There is some evidence that OSCN- and OI- have 
slightly different spectrums of antimicrobial activity. For example, while OSCN- lacks activity 
against RSV in vitro, OI- has anti-RSV activity in vitro and in vivo (Derscheid and Ackermann 
2012; Fischer et al. 2011). The lung also has other oxidative systems with antimicrobial activity 
including the phagocytic NADPH oxidase (Phox), MPO, and nitric oxide synthase. Of these, 
MPO, like LPO, can convert KI and NaSCN to a halide in the presence of H2O2 and neutrophils 
expressing MPO enter lung airways during RSV infection (Nauseef 2013); however, the amount 
of MPO in ASL and extent to which MPO in ASL contributes to halide formation in ASL are not 
known. 
The Duox/LPO defense system has activity against both bacteria and multiple respiratory 
viruses, including RSV and adenovirus (Ad) in vitro (Banfi 2007; Fischer et al. 2011; Gerson et 
al. 2000). To test the potential antiviral activity of this system in vivo, large animal models of 
viral infections are essential because mouse airways lack sufficient LPO and rat airways contain 
only few LPO-secreting cells. The ovine respiratory tract is similar to that of humans in terms of 
LPO and Duox expression and other physiologic and immunologic features. After in vitro 
studies and pilot work in lambs, we developed the hypothesis that the antimicrobial activity of 
Duox/LPO can be optimized in vivo through the supplementation of KI or NaSCN to treat RSV 
and possibly a number of other respiratory infections. Amelioration of respiratory viral infections 
by enhanced oxidative responses is significant because the therapy is relatively inexpensive, 
available, and easily distributed and administered.
The following study assessed the extent to which KI administration (for generation of HOI)
reduces RSV disease in vivo using lambs (Derscheid et al. 2013). NaSCN was not assessed 
because it’s oxidative product, OSCN-, lacks anti-RSV activity in vitro (Fischer et al. 2011).  The 
study included four groups of lambs:  1) Control group (no KI and no RSV); 2) M37 group (no KI 
and challenged with nebulized M37 strain of RSV); 3) KI + M37 (KI administered daily with 
nebulized M37 strain of RSV); and 4) dapsone plus KI and M37 strain of RSV). KI administration 
significantly reduced RSV disease severity, RSV gross lesions, RSV mRNA levels, RSV viral
antigen distribution in lung and RSV viral titers (Fig. 3). This experimental design was repeated
in older lambs (3-week-old lambs) with similar significance (not shown). One group also 
received dapsone and the lack of anti-RSV activity in this group that received dapsone, as
reflected by a markedly increased RSV lung lesions, RNA levels, RSV antigen and RSV titers 
(not shown), confirmed/validated that the anti-RSV effect(s) of KI is mediated by oxidative 
responses and not by KI itself. This is because dapsone inhibits LPO activity, and without LPO 
activity, OI- (the oxidative product of KI in the Duox/LPO reaction) cannot be formed (Bozeman 
et al. 1992; Derscheid et al. 2013). The findings of anti-RSV activity mediated by the Duox/LPO 
oxidative defense system are consistent with those in sheep by Gerson in which dapsone 
administration significantly enhanced colonization of Pasteurella haemolytica (renamed to 
Mannheimia haemolytica) a Gram-negative pathogen of ruminant respiratory tract (Gerson et al. 
2000). P. haemolytica (M. haemolytica) bears much phenotypic and genotypic similarity to 
Haemophilus sp., including H. influenzae. In contrast to the anti-RSV activity mediated by the 
Duox/LPO system, RSV can inhibit the anti-oxidant enzymes of lung epithelia (Hosakote et al. 
2012).
Clara cell protein (CC10). Clara cells are non-ciliated bronchiolar epithelial cells that 
biometabolize xenobiotics, secrete immunomodulatory substances, and are progenitor cells for 
Clara and type II cells (Wang et al. 2010). The Clara cell proliferation pool is vulnerable to 
exhaustion, especially in neonates and chronic smokers (chronic toxin exposure) (Barth et al. 
1994; Derscheid and Ackermann 2013). With Clara cell injury or loss, a proinflammatory 
environment can form due to the loss of immunomodulatory secretions by Clara cells (Wang et 
al. 2003). Clara cells secrete large amounts of Clara cell secretory protein (CCSP), also known 
as CC10 and also known as CC16, secretoglobin, and uteroglobin.  CC10 is increased in 
bronchoalveolar lavage fluid and serum during acute injury such as smoke inhalation or 
application of pneumotoxicants (naphthalene, 4-ipomeanol (4-IM), chloroethylene).  In contrast, 
CC10 is decreased in chronic or dysplastic airway dysfunction (asthma, chronic obstructive 
pulmonary disease, or bronchopulmonary dysplasia (BPD) (Barth et al. 1994; Elizur et al. 2007; 
Wang et al. 2003). With RSV infection, CC10-deficient mice have increased inflammatory 
responses and RSV persistence.  With CC10 expression there is a reduction of inflammatory 
responses and RSV persistence (Derscheid and Ackermann 2013). CC10 may not only have a 
protective effect on Clara cells, but also stimulate development of Clara cells. Clara (and type 
II) cells also produce substances with known anti-RSV activity including:  SP-A, SP-D (which 
bind and opsonize RSV), beta-defensins, beta-galactoside-binding protein, and RSV receptors 
such as retinoic acid inducible gene-1 (RIG-I) which triggers epithelial responses as well as 
inflammatory/immunomodulatory substances (Derscheid and Ackermann 2013; Elizur et al. 
2007). RSV infection enhanced production of secretoglobin (CC10) family proteins in nasal 
mucus secretions from calves infected with bovine RSV (bRSV) (Sacco et al. 2013). 
The extent of CC10 expression in developing fetal lamb lung was measured by qPCR at 50, 75, 
90% gestation, full term and adults.  CC10 levels were low preterm and increased with age after 
birth (Fig. 4); these findings are consistent with the degree of epithelial cell maturation as
determined with periodic acid-Schiff (PAS) stain which detects carbohydrate-like molecules 
(e.g., glycogen). Epithelial cells with increased PAS staining were present during gestation and 
were less mature and produced less SP-A and SP-D than term and adult lambs. The 
expression of CD208+ (type II cells) and CD208- cells (Clara cells) were reduced preterm which 
is also consistent with immaturity (Meyerholz et al. 2006).
CC10 reduces RSV M37 severity. In a pilot study, we have assessed the effects of 
recombinant human CC10 (rhCC10) in preventing RSV M37 pneumonia. Briefly, two lambs 
received rhCC10 intravenously (1.5 mg/kg) twice daily one day prior to RSV inoculation and 
each day thereafter until lungs were collected on day 6 post RSV inoculation (6 ml, 107 PFU/ml 
via nebulizer); another group of lambs (n = 6) received RSV alone and no rhCC10; a third group 
lacked rhCC10 and were nebulized with media (control). Lambs receiving rhCC10 had no side 
effects from inoculation. rhCC10-treated lambs had reduced gross lesions and decreased RSV 
mRNA levels by RT-qPCR (Fig. 5). 
ALX-0171. Ablynx NV, has developed a therapeutic protein based on a camelid variable heavy
chain only (VH/H) immunoglobin backbone with strong binding affinity to the F (fusion) protein of 
the RSV virus, thereby inhibiting RSV fusion to target cells. Briefly, ALX-0171 is composed of 
VH/H chains linked to form a trivalent binding structure with a 2,000 fold increase in potency 
compared to monovalent structures. ALX-0171 is delivered through nebulization and it is highly 
stable. ALX-0171 has demonstrated antiviral efficacy in both in vitro and in vivo studies, the 
latter being performed in the cotton rat therapeutic model for RSV.  In order to further assess 
the extent to which ALX-0171 may treat RSV infections in vivo, ALX-0171 is currently being 
assessed in neonatal lambs infected with a human RSV strain (hRSV M37). The lamb studies 
demonstrate the capacity of the lamb model to characterize delivery, distribution and efficacy of 
a nebulized drug formulated to treat RSV infection in infants.
RSV Vaccination in lambs.  Recently, we have shown that the newborn lamb develops 
enhanced RSV lesions following vaccination with a formalin-inactivated RSV (FI-RSV) vaccine
(Derscheid et al. 2014).  This work was completed in lambs deprived of colostrum which 
eliminated the potential influence of maternal antibodies.  This study sets the stage for 
additional work in lambs in regards to understanding FI-RSV pathogenesis and for assessment 
of vaccines.
Refining RSV Models.  Experimental RSV infection in lambs and other models requires 
constant assessment and validation of basic methods.  As indicated, lambs are susceptible to 
various human (Long, A2, Memphis 37 strain) and bovine strains (bRSV) of RSV as well as 
ovine parainfluenzavirus 3 (ovine PI-3) and a human strain of parainfluenzavirus 3 (PIV-3)
(Derscheid and Ackermann 2012).  All of these are enveloped viruses and must be 
administered with suitable physiologic conditions.  RSV and PI-3, PIV-3 can be delivered by 
intranasal inoculation with a syringe or atomizer, intrabronchially with a fiberoptic bronchoscope, 
intratracheally with a syringe and needle and with whisper jet nebulizers (Derscheid and 
Ackermann 2012; Derscheid et al. 2013; Meyerholz et al. 2007; Olivier et al. 2009).  For 
nebulization, we have shown that the addition of sucrose at 15-20% reduces RSV loss during 
nebulization and enhances RSV disease severity (manuscript under review).  Work by others 
demonstrated that RSV grown in Vero cells have truncated G glycoprotein which altered 
infectivity in vitro.  Similarly, our recent work in lambs demonstrated that RSV grown in Hep2 
cells have increased virulence compared to RSV grown in Vero cells (Derscheid et al. 2013).
Effects of ethanol on fetal lung development and innate immunity.  Maternal ethanol 
consumption is a risk factor for preterm birth and the enhanced severity of RSV in preterm 
infants is well known (Albertson and Gronbaek 2004; Aujard and Fauroux 2002; Garcia et al. 
2010; Sommer et al. 2012). It is possible that ethanol increases RSV disease severity beyond 
that of preterm birth alone due to Clara cell damage or alteration in development/function. If 
true, other toxins or unknown substances reaching the fetal lung in utero may affect Clara cells 
and thus, susceptibility to RSV infection (Lazic et al. 2010; Lazic et al. 2011; Lazic et al. 2007).
Clara cells biometabolize toxins and other substances knowingly or unknowingly consumed by 
pregnant mothers (e.g., ethanol, nicotine) (Lazic et al. 2010; Lazic et al. 2011; Lazic et al. 2007).
Ethanol and other toxins can injure Clara cells and nearby type II cells resulting in reduced 
innate immunity and increased susceptibility for RSV infection (Derscheid and Ackermann 2012; 
Derscheid and Ackermann 2013). Despite the fact that ethanol has detrimental effects on the 
developing fetus, one out of 29 pregnant women consumes alcohol during pregnancy and 
another survey found that 5 to 10 out of 1000 pregnant women consume 7 or more drinks per 
week (Ethen et al. 2009; Jaddoe et al. 2007). While ethanol has effects on the nervous system 
and liver, the detrimental effects of ethanol on developing fetal lung are of increasing concern. 
Ethanol decreases surfactant synthesis and pro-inflammatory cytokines and impairs response to 
bacterial challenge. Clara cells produce cytochrome CYP2E1 which biometabolize ethanol to 
acetaldehyde and malondialdehyde (MDA). These form protein adducts, invoke inflammatory 
responses, and reduce repair of bronchiolar epithelium. 
The effects of ethanol on prenatal lamb lung development has been developed by delivering 
ethanol to gestating ewes resulting in blood levels consistent with a moderate drinker, which is 
the most common form of ethanol consumption by pregnant women (Ethen et al. 2009; Jaddoe 
et al. 2007; Lazic et al. 2011; Lazic et al. 2007; Sozo et al. 2009). Our work shows that ethanol-
exposed lambs have reduced epithelial maturation, ciliary function, innate immune gene 
expression of surfactant protein A and D (SP-A, SP-D), TNF alpha, IL-10, and monocyte 
chemotactic protein (MCP-1) by lung epithelia along with striking reductions in hypoxia-inducible 
IDFWRU +,) Į DQG Į YDVFXODU HQGRWKHOLDO JURZWK IDFWRU 9(*) DQG 9(*) UHFHSWRUV
(VEGFR) (Lazic et al. 2011; Lazic et al. 2007). SP-A and SP-D have antimicrobial activity 
against RSV and enhance macrophage activation (Lazic et al. 2011; Lazic et al. 2007). Loss of 
these innate immune and inflammatory responses increases susceptibility to infection 
(Derscheid and Ackermann 2013; Krishnan et al. 2003; Starner et al. 2005; Stokes et al. 2013).
Ethanol-induced changes in lung development and immunity in lambs have been confirmed by 
the Harding laboratory and sheep are used for other types of ethanol studies (Sozo et al. 2009).
The precise effect of ethanol on fetal Clara cells is not known but being assessed (below).
Maternal ethanol consumption alters transcriptomes of developing ovine lung (Derscheid and 
Ackermann 2012).  RNA expression levels in RNA from lung of four lambs were determined by 
Next-Generation Sequencing (NGS) with Illumina NGS on GAIIx (1 x 40 cycles/bases single 
read) and HiSeq 2000 (2 x100 cycles/bases, paired-end). Two lambs were preterm and two 
were term; of these, one preterm and one term lamb were exposed to ethanol in utero (maternal 
consumption) and the other two lambs were not exposed to ethanol at any time. Data analysis 
was with SCS/RTA, TopHat workflow, and Cufflinks, Cuffcompare and Cuffdiff. Transcripts with 
increased expression in preterm lung exposed to ethanol included genes related to: 1)
Inflammation, immunity and growth factors:  lysozyme, Secreted frizzled-related protein 2, 
SFRP2 which affects Wnt signaling, Interleukin 12 A, CXCL10, insulin-like growth factor-1, IGF-
1, Fos, IGF binding protein 5; early growth response protein 1, EGR1, CD28, CD4; 2)
Metabolism/stress:  leptin receptor, LEPR, serotonin transporter, SERT; 3) Cell proliferation 
inhibition: CDKN1C, p57, a Kip2 cell proliferation inhibitor and 4) Angiogenesis/vascularization: 
SERPINF1 (PEDF). Genes down-regulated by ethanol but up-regulated by RSV include:  IL-8, 
71)Į,&$0-1. 
Conclusions.  The various animal models of RSV infection contribute to the broad 
understanding of the RSV pathogenesis.  The lamb model has several features consistent with 
RSV in infants which allows insight into epithelial cell infection, pathogenesis, development of 
bronchiolitis and its effect on airflow and gaseous exchange, inflammatory responses, innate 
and adaptive immune responses.  The ability to study lambs born preterm is one of several 
unique features of the lamb model.  Also, the lamb model is conducive to therapeutic 
interventions; especially those that are mechanistic and at a fundamental level. While VEGF 
and CC10 can enhance a wide-variety of immunomodulators that mediate resistance to RSV 
infection, ALX-0171 is a very precise inhibitor of RSV.  Enhancement of oxidative defense 
(Duox/LPO) through KI administration invokes oxidative radical defense against RSV and 
potentially other viruses and microbial agents. Lambs develop enhanced RSV disease if 
vaccinated with formalin-inactivated RSV (FI-RSV) which opens up the model to studies of FI-
RSV enhanced disease and assessment of vaccines.  The ability to deprive lambs of maternal 
antibodies is advantageous feature of the lamb model with is particularly useful in assessment 
of vaccines. The findings that maternal ethanol consumption alters development and innate 
immunity of the lung in utero may explain, at least in part, why ethanol is a risk factor for preterm 
birth and also predispose the infant lung to increased RSV disease severity.  
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FIGURE LEGENDS
Figure 1:  Respiratory syncytial virus strain A2 causes bronchiolitis in lambs (Olivier et al. 
2009). A. Lung from a control lamb not infected with RSV that contains a bronchiole and
alveoli. B.  Lung from a lamb 6 days post-inoculation with RSV with a bronchiole (outlined) 
containing epithelial cells admixed with neutrophils (*).  Alveoli around the bronchiole are 
collapsed with accumulation of degenerate neutrophils and areas of necrosis (arrow). C and D.
Immunohistochemical detection of RSV antigen in lung from a lamb 6 days post-inoculation with 
RSV, in which RSV viral antigen is present within the bronchi, epithelial cells lining the bronchi,
and the syncytial cells in areas of alveolar consolidation.  Bars = 25 μm.
Figure 2: Pretreatment with exogenous rhVEGF decreases histologic consolidation 
score of lambs infected with hRSV A2 strain (Olivier et al. 2011).  Lambs received either 
media followed by RSV A2 (no VEGF) or rhVEGF followed by RSV A2 and were assessed for 
clinical signs, viral lesions and mRNA levels.  At six days post RSV A2 infection VEGF-treated 
lambs had reduced histologic consolidation scores (an overall score of bronchiolitis and lung 
inflammation) indicating a decreased in alveolar consolidation and inflammatory cell infiltration 
(*p<0.05). Exogenous rhVEGF treatment also reduced RSV mRNA levels as 4 and six days 
post RSV inoculation (not shown).  Previous studies have demonstrated the VEGF treatment 
also reduces the severity bovine RSV (bRSV) in newborn lambs (not shown).
Figure 3: Respiratory syncytial virus Memphis 37 strain causes bronchiolitis in lambs 
that is reduced with enhanced airway oxidative responses.  A. Lung from a lamb infected 
with RSV M37 strain four days post inoculation in which there is erosion of the epithelium with 
accumulation of cell debris in the airway lumen and formation of a syncytial cell. B.  Lung from 
a lamb 6 days post-inoculation with RSV M37 strain in which viral antigen is detected by 
immunohistochemistry and viral antigen is present with epithelial cells, macrophages and in cell 
debris of the airway lumen.  There is moderate thickening of the epithelium due to hyperplasia.
C.  Enhancement of the airway oxidative response (Duox/LPO oxidative system) by 
administration of potassium iodide (KI) reduces RSV M37 mRNA levels (as well as viral titers, 
antigen and lesions; not shown) in RSV M37-inoculated lambs treated with KI (M37 + KI) 
compared to lambs inoculated with RSV M37 but not receiving KI (M37).  Inhibition of the 
oxidative defense system with dapsone (DAP) in a group of lambs resulted in significantly 
enhanced RSV M37 RNA levels (DAP + M37 + KI) despite KI treatment (Derscheid et al. 2013).  
Figure. 4. CC10 reduces RSV gross lesions and RSV mRNA levels. Two lambs received 
rhCC10 intravenously (1.5 mg/kg) twice daily one day prior to RSV inoculation (6 ml, 107 
PFU/mL via nebulizer) and each day thereafter; another group of lambs (n = 6) received RSV 
alone and no rhCC10; a third group lacked rhCC10 and were nebulized with media (control). 
rhCC10-treated lambs had reduced gross lesions and decreased RSV mRNA levels by qPCR. 
Figure. 5. Maternal ethanol consumption reduces lung maturation through hyxpoxia 
inducible factor (HIF) and it’s downstream gene vascular endothelial growth factor 
(VEGF) (Lazic et al. 2011).  Fig. 5A.  Relative mRNA expression of hypoxia inducible factor-Į
ĮDQGĮ +,)-Į+,)-ĮDQG+,)-Į UHVSHFWLYHO\ LQ WKHQHRQDWDO RYLQH OXQJ([SRVXUH WR
ethanol in utero reduced mRNA expression of HIF-ĮDQG+,)-ĮLQWKHOXQJVRISUH-term (PT) 
lambs when compared to the control lambs of the same age group. Such changes are not 
observed in the lungs of full-term (FT) lambs exposed to ethanol in utero. No significant
changes are seen with HIF-ĮP51$ H[SUHVVLRQ OHYHOV LQ ERWK 37 DQG )7 ODPEV S
significance was established at 90% confidence interval).  Fig. 5B. Relative mRNA expression 
of vascular endothelial growth factor (panVEGF) in the neonatal ovine lung. Exposure to ethanol 
in utero reduces mRNA expression of panVEGF in the lungs of pre-term (PT) lambs when 
compared to the control lambs of the same age group. Such changes are not observed in the 
lungs of full-term (FT) lambs exposed to ethanol in utero. (*p<0.1, significance was established 
at 90% confidence interval). Fig. 5C. Relative mRNA expression of vascular endothelial growth 
factor receptor 1 and 2 (VEGFR-1 and VEGFR-2 respectively) in the neonatal ovine lung. 
Exposure to ethanol in utero reduces mRNA expression of VEGFR-1 and VEGFR-2 in the lungs 
of pre-term (PT) lambs when compared to the control lambs of the same age group. Such 
changes are not observed in the lungs of full-term (FT) lambs exposed to ethanol in utero.
(*p<0.1, significance was established at 90% confidence interval).  Fig. 5D. Periodic acid-Schiff 
(PAS) stain for glycogen granules in the type II pneumocytes (ATII). Glycogen granules in the 
ATII are more abundant in the pre-term lambs exposed to ethanol in utero (B) when compared 
to the to the control lambs of the same age group (A). Glycogen content in the ATII is similar in 
the full-term lambs exposed to ethanol in utero (D) and the control lambs of the same age group 
(C). 
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